clinical trial · NCT05587712
Study to Evaluate Sotatercept (MK-7962) in Children With Pulmonary Arterial Hypertension (PAH) (MK-7962-008)
Merck Sharp & Dohme LLC·phase2·recruiting·n = 42
Pulmonary Arterial HypertensionSotatercept
brief summary
The primary objectives of the study are to evaluate the safety and tolerability, and pharmacokinetics (PK) of sotatercept over 24 weeks of treatment in children ≥1 to \<18 years of age with PAH World Health Organization (WHO) Group 1 on standard of care (SoC). There is no formal hypothesis.
started
Jan 19, 2023
primary completion
Sep 21, 2028
completion
Sep 21, 2028
last updated
Apr 20, 2026
official title
A Phase 2 Open-label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Sotatercept (MK-7962) in Children From 1 to Less Than 18 Years of Age With PAH on Standard of Care
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol